Seventy Percent Of Newly Diagnosed Alzheimer’s Disease Patients Do Not Receive Treatment Within A Year Of Diagnosis

February 24, 2009 at 11:00 am Leave a comment


Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that 70.7 percent of newly diagnosed Alzheimer’s disease patients do not receive treatment within a year of being diagnosed. The reasons for this are due to their denial, preference for no drug therapy, concerns about cost or the side-effect and safety risks associated with drug treatment. The new report entitled Treatment Algorithms in Alzheimer’s Disease finds that while surveyed neurologists primarily attribute their decision not to prescribe treatment for newly diagnosed Alzheimer’s disease patients to patient prerogatives, surveyed primary care physicians (PCPs) also cite presence of mild disease as a factor to delay drug treatment.



The report also finds that surveyed neurologists and PCPs both keenly anticipate the integration of disease-modifying therapies into Alzheimer’s disease treatment; 72 percent of surveyed neurologists and 63 percent of surveyed PCPs report that they are “very likely” or “likely” to prescribe disease-modifying therapies first line upon their launch. However, uptake of a given disease-modifying therapy will be strongly modulated by its safety profile, as an agent with a risk for more severe side effects is likely to be prescribed primarily by neurologists.



“Surveyed PCPs’ enthusiasm exists despite the fact that only eight percent of them are aware of any one of the potential disease-modifiers, such as Elan/Wyeth’s bapineuzumab, that are expected to launch by 2012,” said Madhuri Borde, Ph.D., analyst at Decision Resources. “In contrast, 45 percent of surveyed neurologists know of bapineuzumab, and 65 percent of this group believes that they will prescribe the drug if it is approved.”



About Treatment Algorithm Insight Series



Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians’ prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.



About Decision Resources



Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.



About Decision Resources, Inc.



Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresources.com.



All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



Decision Resources

http://www.decisionresources.com

[Via http://www.medicalnewstoday.com]

Advertisements

Entry filed under: Uncategorized.

Organised Crime Gang Targets HIV/AIDS Patients In Internet Scam Benvenue Medical Receives CE Mark Approval For Kiva™ VCF Treatment System

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Archives

Top Clicks

  • None

Blog Stats

  • 15,594 hits

%d bloggers like this: